

---

**Product Data Sheet**


---

Product Name: CI-NQTrp

Cat. No.: GC61887

**Chemical Properties**

Cas. No. 185351-23-9

SMILES C1C(C(C1=C(C=CC=C1)C2=O)=O)=C2N[C@H](C(O)=O)CC3=CNC4=C3C=CC=C4

Formula C<sub>21</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>4</sub>

M.Wt 394.81

Solubility DMSO : 250 mg/mL (633.22 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

CI-NQTrp significantly disrupts the preformed fibrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein[1][2].

CI-NQTrp efficiently disassembled pre-formed PHF6 peptide fibrils[1]. CI-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers[1].

CI-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both A $\beta$  and tau[2]. CI-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29[2].

## References:

- [1]. V Guru KrishnaKumar, et al. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids. Sci Rep. 2018 Jan 8;8(1):71.  
 [2]. Moran Frenkel-Pinter, et al. CI-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. Neurodegener Dis. 2017;17(2-3):73-82.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---